FDA
7th June 2013

FDA Drug Advisory Committee – Changes to DSaRM and more!

At ISS we know the importance of understanding your audience at an FDA AdComm – what are their backgrounds, are they motivated by a particular cause or issue?

FDA Drug Advisory Committee – Changes to DSaRM and more!

At ISS we know the importance of understanding your audience at an FDA AdComm – what are their backgrounds, are they motivated by a particular cause or issue? Based on our knowledge we are happy to kick-off the ISS roll call blog – a designated reporter of the changes to the FDA Drug AdComm members.

This month we saw a change in a well-known committee – 4 members of the Drug Safety and Risk Management Advisory Committee (DSaRM) have the left the committee. Drs. William Cooper, Peter Kaboli, Elaine Morrato and T. Mark Woods have all reach the end of the terms this past month. DSaRM now has four vacancies to fill and we wait anxiously to see who fills those spots.

The Anesthetic and Analgesic Drugs Advisory Committee has also seen some departures this month. It was the end of term for Drs. Edward Covington, John Markman and Mr. Knox Todd. Consumer representative Penny Cowan has also reached the end of her term. The departure of these members leaves a total of 6 vacancies on this committee.

Heading into the summer we will be regularly scanning the committees to report on new additions to these and all other FDA Drug AdComms. Click here for the current remaining DSaRM committee and here for the remaining Anesthetic and Analgesics Drugs committee.

Stay tuned for our next blog post where we will put the spotlight on one of the hottest AdComms – the Oncologic Drug Advisory Committee.

ISS has over a decade of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComms per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact info@innovativescience.net.

Recent Related Articles

Best Tips for Medical Device Manufacturers to Write a Compelling Substantial Equivalence Section for their FDA 510k Submission
01 July 2020
Best Tips for Medical Device Manufacturers to Write a Compelling Substantial Equivalence Section for their FDA 510k Submission

Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more

Evolving FDA Thinking on Advisory Committee Meetings Related to Foods, Drugs, and Devices
25 June 2020
Evolving FDA Thinking on Advisory Committee Meetings Related to Foods, Drugs, and Devices

FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more

NDA vs. OTC Monograph: Which Pathway is Right for You?
22 June 2020
NDA vs. OTC Monograph: Which Pathway is Right for You?

One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more

4 Problems Importing Rapid Antibody Tests for Coronavirus
19 June 2020
4 Problems Importing Rapid Antibody Tests for Coronavirus

US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more

Let’s work together

The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us today

Contact us